These findings underscore the central role of p300/CBP in sustaining oncogenic enhancer activity and establish PROTAC-mediated degradation as a promising therapeutic strategy for enhancer-addicted prostate cancers. The gene discussed is EP300; the disease is Familial prostate cancer.